US-based biotechnology company Aura Biosciences raised $22m yesterday in a series B round featuring Chiesi Ventures, the corporate venturing arm of pharmaceutical company Chiesi Group, and scientific measuring instruments manufacturer Li-Cor Biosciences.
The round was led by venture capital firm Advent Life Sciences. Property debt manager Alexandria Real Estate Equities’ investment vehicle Alexandria Venture Investments, VC firm Ysios Capital and angel investor Henri Termeer also took part.
Aura is developing treatments for rare cancers of the eye based on nanoparticles…
